Infection Survival Rate of Covid-19 – Stanford University Study

Featured

Infection Survival Rate of Covid-19 – Stanford University Study

By all historical notions of pandemic fatalities, there was no pandemic in 2020-21. The average % risk of death in any one year for the 70+ is not too dissimilar even without this respiratory virus.

Pre-print:
Drs Ioannidis & Axfors at Stanford

Age Infection Survival Rate
0-19 99.9973%
20-29 99.986%
30-39 99.969%
40-49 99.918%
50-59 99.73%
60-69 99.41%
70+ 97.6% (not in care homes or hospitals)
70+ 94.5% (all)

This is data taken from 2020 when most doctors did not know or implement adequate treatments.

With treatments and honest numbers these numbers would be much higher. This is a worst case scenario infection survival rate.

https://www.medrxiv.org/content/10.1101/2021.07.08.

We are The People

Featured

Each household grows their own food and then share between each other, get your children involved and make it fun, just like the good old days. And cut out the big companies that are killing us with poisonous chemicals in our foods. People Power Not Corporations

Fourth Industrial Revolution

Featured

“The transition from using Covid to using Climate Change as the justification for implementing the Fourth Industrial Revolution and the “digital transformation” of the economy and society is well underway” – Whitney Webb

Be Aware of a “SHILL”

Featured

A shill, also called a plant or a stooge, is a person who publicly helps or gives credibility to a person or organization without disclosing that they have a close relationship with said person or organization. Shills can carry out their operations in the areas of media, journalism, marketing, politics, sports, confidence games, or other business areas. A shill may also act to discredit opponents or critics of the person or organization in which they have a vested interest.

Clinical Trials

Featured

Sponsor: BioNTech SE, Collaborator: Pfizer, Information provided by (Responsible Party): BioNTech SE
Estimated Study Completion Date : May 2, 2023
https://clinicaltrials.gov/ct2/show/nct04368728

Sponsor: ModernaTX, Inc., Collaborator: Merck Sharp & Dohme Corp., Information provided by (Responsible Party): ModernaTX, Inc.
Estimated Study Completion Date : June 30, 2024
https://clinicaltrials.gov/ct2/show/nct03897881

Sponsor: AstraZeneca, Collaborator: Iqvia Pty Ltd, Information provided by (Responsible Party): AstraZeneca.
Estimated Study Completion Date : February 14, 2023
https://clinicaltrials.gov/ct2/show/nct04516746